Propanc Biopharma Inc

PPCB Healthcare Biotechnology

In the quarter to June 2026, EPS fell 99.6%, free cash flow fell 1,637.4% and total debt fell 21.4%, each against the same quarter a year earlier.

0.34 0.00 0.00%
Market cap
$3.5M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Jun '17 Jun '18 Jun '19 Jun '20 Jun '21 Jun '22 Jun '23 Jun '24 Jun '25 Jun '26
Current Ratio
0.01 0.01 0.02 0.02 0.00 0.00 0.01 0.01 1.50 2.55
Net Debt/EBITDA
0.00 (0.01) (0.02) 0.00 (0.03) (0.02) (0.06) (0.20) (0.01) 0.02
Debt/Equity
(0.01) (0.01) (0.01) (0.01) (0.02) (0.02) (0.04) (0.09) 0.04 0.05
ROE
196.27% 115.36% 104.10% 119.22% 71.97% 110.09% 101.75% 58.39% (1,163.68%) (169.86%)
ROA
(3,318.22%) (8,455.50%) (6,653.26%) (4,735.96%) (4,332.80%) (7,085.23%) (4,403.94%) (3,034.66%) (598.08%) (122.15%)
ROIC
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% (247.22%) (125.86%)
Return on Tangible Assets
144.52% 104.22% 133.81% 129.34% 78.76% 110.26% 99.61% 53.09% (2,123.67%) (381.25%)
Average Days of Receivables
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Free Cash Flow per Share
(0.58) (55.27) (3.93) (75.19) (0.38) (21.06) (0.64) (9,351.00) (2.55) (5.06)
Book value per Share
(1.55) (171.37) (8.19) (148.02) (1.01) (44.33) (1.79) (37,791.00) 87.63 8.37
Free Cash Flow
(2.05) (2.18) (2.06) (1.85) (1.15) (1.44) (1.11) (0.94) (0.41) (5.69)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 6 Oct 2026